{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:58:21Z","timestamp":1771012701504,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s35029","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T22:21:22Z","timestamp":1381962082000},"page":"337","source":"Crossref","is-referenced-by-count":2,"title":["Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety"],"prefix":"10.2147","author":[{"given":"J\u00f6rg","family":"Trojan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Welker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,10]]},"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=17860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:36:49Z","timestamp":1477867009000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/antiangiogenic-treatment-in-hepatocellular-carcinoma-the-balance-of-ef-peer-reviewed-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/cmar.s35029","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}